The Short Answer
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are closely related compounds involved in the pathways your body uses to produce NAD+, a coenzyme essential to normal cellular metabolism. Human studies have investigated both compounds and reported changes in NAD+-related biomarkers. However, current evidence does not establish that either NMN or NR produces superior health outcomes. (R)
↓ Jump to
Estimated reading time: 8 minutes
- NMN vs NR at a glance
- What is NMN?
- What is NR?
- What is the difference between NMN and NR?
- How do NMN and NR become NAD+?
- Does NMN or NR raise NAD+ more?
- What does human research tell us about NMN vs NR?
- Is NMN better than NR?
- What does research say about NMN vs NR bioavailability?
- What have human studies reported about tolerability?
- What doses of NMN and NR have been studied in humans?
- Which has stronger human evidence: NMN or NR?
- How are NMN, NR and NAD+ related?
- Does the evidence show that NMN or NR is better?
One of the most interesting things about NMN and NR is that their chemical relationship looks deceptively simple. NMN sits one biochemical step closer to NAD+ than NR in a simplified NAD+ biosynthesis pathway. Yet direct human research published in 2026 found that NMN or NR produced comparable increases in baseline whole-blood NAD+ after 14 days. (R) That finding highlights an important principle when comparing NMN vs NR: being closer to NAD+ in a biochemical pathway does not, by itself, demonstrate a greater effect in humans.
NMN vs NR at a glance
Before looking more closely at the evidence, it helps to understand exactly how NMN and NR are related. Both participate in NAD+ metabolism, but they have different chemical structures and occupy different positions in NAD+ biosynthesis.
| Feature | NMN | NR |
|---|---|---|
| Full name | Nicotinamide mononucleotide | Nicotinamide riboside |
| Relationship to NAD+ | NAD+ precursor | NAD+ precursor |
| Structural difference | Contains a phosphate group | Does not contain a phosphate group |
| Simplified pathway | NMN → NAD+ | NR → NMN → NAD+ |
| Human research | Growing evidence base | Longer-established evidence base |
| Direct human comparison | Emerging | Emerging |
| Superior health outcomes? | Not established | Not established |
The most important distinction is between biochemical mechanism and demonstrated human outcomes. NR can be phosphorylated to form NMN before subsequent NAD+ synthesis, but this additional biochemical step does not establish that one precursor is superior to the other. (R)
What is NMN?
NMN, or nicotinamide mononucleotide, is an intermediate involved in NAD+ biosynthesis. Understanding NMN therefore starts with understanding NAD+ itself. NAD+, or nicotinamide adenine dinucleotide, is a coenzyme involved in cellular redox reactions and normal energy metabolism. It also acts as a substrate for NAD+-consuming enzymes involved in cellular signalling. (R)
NMN has been investigated in human clinical research using a range of study designs, populations and doses. For example, a randomised trial involving older men investigated 250 mg per day for 12 weeks and reported changes in whole-blood NAD+ and NAD+-related metabolites. (R)
Another randomised trial involving 25 postmenopausal women with prediabetes investigated 250 mg per day for 10 weeks. Researchers reported changes in muscle insulin-stimulated glucose disposal, while several other metabolic measures did not change significantly. (R) These findings are best interpreted within the specific populations, doses and durations studied rather than as evidence of general health effects.
What is NR?
NR, or nicotinamide riboside, is another compound involved in NAD+ biosynthesis. Although closely related to NMN, its position in the pathway is slightly different. Inside cells, NR can be phosphorylated by nicotinamide riboside kinases to form NMN. NMN can subsequently participate in NAD+ biosynthesis. (R)
NR has been examined in numerous human studies. An early pharmacokinetic investigation reported dose-dependent changes in the blood NAD+ metabolome following oral NR at studied doses of 100, 300 and 1,000 mg. (R)
A later eight-week randomised controlled trial involving 140 adults with overweight investigated 100, 300 and 1,000 mg of NR per day. Researchers reported dose-dependent increases in whole-blood NAD+ during the study. (R) These studies demonstrate effects on measured NAD+-related biomarkers. They should not be interpreted as establishing broader health benefits that were not demonstrated by the research.
What is the difference between NMN and NR?
The clearest difference between NMN and NR is structural. NMN contains a phosphate group, while NR does not.
That difference also affects their positions in a simplified NAD+ biosynthesis pathway:
NR → NMN → NAD+
NMN → NAD+
NR therefore undergoes phosphorylation to form NMN before subsequent NAD+ synthesis. (R) However, this simplified diagram does not describe everything that happens after these compounds are consumed. Digestion, extracellular metabolism, the gut microbiome, transport and tissue-specific metabolism may all influence how NAD+ precursors are processed.
How do NMN and NR become NAD+?
Your body maintains NAD+ through interconnected biosynthetic and recycling pathways rather than a single linear process. NMN and NR can enter this network at different points. Cellular research has found evidence that extracellular NMN can be dephosphorylated to NR before cellular uptake, with NR then converted back to NMN through NRK1-dependent metabolism. (R)
A mouse study published in 2019 proposed another mechanism by identifying SLC12A8 as a transporter involved in NMN uptake in the small intestine. (R) However, this interpretation was subsequently challenged, and direct NMN transport through SLC12A8 should therefore not be presented as an established human absorption mechanism. (R)
More recent human research has added another possibility. A 2026 study reported that NMN and NR produced nicotinic acid during ex vivo fermentation with human gut microbiota and proposed that microbial metabolism may contribute to their effects on circulating NAD+. (R) This remains an evolving area of research, particularly when translating biochemical and preclinical mechanisms into human physiology.

Does NMN or NR raise NAD+ more?
Current human evidence does not establish that NMN consistently raises NAD+ more than NR, or that NR consistently raises NAD+ more than NMN. A 2026 study involving 65 healthy adults directly investigated nicotinamide, NR, NMN and placebo. After 14 days, the groups receiving NR or NMN both showed approximately two-fold increases from baseline in whole-blood NAD+. (R)
Another small 2026 crossover pharmacokinetic study involving six participants reported differences in blood NAD responses between NR and NMN under the conditions studied. (R)
What does human research tell us about NMN vs NR?
Human evidence is more informative than simply comparing the chemistry of the two molecules. The table below summarises several representative trials and makes their differences easier to see.
| Study | Participants | Compound and studied dose | Duration | Reported finding |
|---|---|---|---|---|
| Christen et al., 2026 (R) | 65 across four groups | NMN or NR, 1,000 mg/day | 14 days | Both groups showed comparable increases from baseline in whole-blood NAD+ |
| Sakuri et al., 2022 (R) | 42 older men | NMN, 250 mg/day | 12 weeks | Changes in whole-blood NAD+ and related metabolites were reported |
| Conze et al., 2019 (R) | 140 adults | NR, 100, 300 or 1,000 mg/day | 8 weeks | Dose-dependent increases in whole-blood NAD+ were reported |
| Elhassan et al., 2019 (R) | 12 older men | NR, 1,000 mg/day | 21 days | Changes in the skeletal-muscle NAD+ metabolome were reported |
| Yoshino et al., 2021 (R) | 25 women | NMN, 250 mg/day | 10 weeks | Changes in muscle insulin sensitivity and NAD+-related metabolism were investigated |
Taken together, these studies indicate that both NMN and NR interact with human NAD+ metabolism. They do not demonstrate that either compound produces superior long-term health outcomes. The evidence base also has important limitations. Many studies are relatively small and short, use different populations and endpoints, and cannot be directly compared as though they were parts of a single trial.
Is NMN better than NR?
Current human evidence does not establish that NMN is better than NR, or vice versa. This is one of the most important conclusions of an evidence-based NMN vs NR comparison. NMN’s position one biochemical step closer to NAD+ does not demonstrate superior human effects.
The emerging direct comparison evidence reinforces that distinction. In the 2026 study described above, equal studied doses of NMN and NR produced comparable increases from baseline in whole-blood NAD+ over 14 days. (R) Whether either precursor produces different long-term physiological outcomes remains an open research question.
What does research say about NMN vs NR bioavailability?
There is currently insufficient direct human evidence to conclude that NMN is more bioavailable than NR, or that NR is more bioavailable than NMN. Bioavailability describes the extent and rate at which a substance or its relevant metabolites become available in the body. For NAD+ precursors, this is more complicated than asking which intact molecule crosses a cell membrane.
Laboratory research has supported extracellular conversion of NMN to NR, mouse research has proposed SLC12A8-mediated NMN transport, and newer human research suggests that gut microbial metabolism may also contribute to NAD+ precursor metabolism. (R) (R) (R) These are distinct types of evidence. Preclinical transport mechanisms should not be presented as proof of superior absorption in humans.
What have human studies reported about tolerability?
Human trials have reported tolerability findings for both NMN and NR, but those observations need to be interpreted within the doses, populations and relatively short durations studied. For example, a 12-week NMN study involving older men reported no serious adverse events attributed to the intervention under the conditions studied. (R) An eight-week NR trial examining 100, 300 and 1,000 mg per day reported no significant difference in the frequency of adverse events between the NR and placebo groups. (R)
These results describe what researchers observed during individual trials. They do not establish that NMN or NR is universally safe, free from side effects or suitable for every person. Long-term evidence is also more limited than short-term human evidence.
What doses of NMN and NR have been studied in humans?
Human trials have investigated different doses of NMN and NR. These are research protocols, not recommendations for personal use. NMN studies have investigated doses including 250 mg per day over periods of 10 to 12 weeks. (R) (R)
NR trials have investigated daily doses ranging from 100 to 1,000 mg in controlled human research, while other study designs have investigated different amounts. (R) Study doses cannot be separated from the populations, duration and research objectives for which they were used. A dose appearing in a clinical trial should therefore not be interpreted as an established or personalised dose for healthy ageing.
Which has stronger human evidence: NMN or NR?
NR has a longer history of published human research, while human research into NMN has expanded substantially in recent years. However, the number of published studies alone does not determine which compound has stronger evidence. When you assess evidence quality, study design, participant numbers, population, duration, outcome measures, funding, conflicts of interest and independent replication all matter.
The recent appearance of direct NMN-versus-NR research is particularly useful because researchers can compare the compounds under the same experimental conditions. Even so, the current head-to-head evidence remains too limited to establish superiority for long-term health outcomes. (R) This is an area where future research may meaningfully change the evidence picture.
How are NMN, NR and NAD+ related?
NAD+ is the coenzyme at the centre of this comparison, while NMN and NR are compounds that can contribute to pathways involved in its biosynthesis. In a simplified pathway, NR can be converted into NMN, while NMN can subsequently contribute to NAD+ formation. (R)
That shared relationship explains why NMN and NR are often compared. They are chemically distinct compounds, but their metabolism intersects with the same NAD+-related biochemical network. NAD+ itself participates in fundamental cellular processes, including redox reactions associated with normal energy metabolism. (R)
Does the evidence show that NMN or NR is better?
At present, human research does not establish a universal winner in the NMN vs NR comparison. Both compounds have been investigated in human research, and studies have reported changes in NAD+-related biomarkers following administration of each precursor. Direct comparative evidence is now emerging, but differences in study design, duration, populations and endpoints mean broad claims of superiority are not justified. (R)
That uncertainty is scientifically useful rather than disappointing. Research into NAD+ metabolism is developing quickly, and newer studies are helping researchers understand how precursor metabolism may involve cells, tissues and even the gut microbiome. Healthy ageing is influenced by many interconnected factors. Regular physical activity, nutritious eating patterns, restorative sleep and other sustainable lifestyle behaviours remain important foundations for long-term wellbeing.
Read our NMN Guide to learn more about the relationship between NAD+ and its metabolic precursors.








